Key Updates in the Treatment of HER2-Positive Breast Cancer

Gain expert insights on current and emerging HER2-targeted therapies for patients with HER2-positive metastatic breast cancer, including best practice for managing treatment-related adverse events.
person default
Jeremy M. Force, DO, MA
Nicholas P. McAndrew, MD, MSCE
Sara Tolaney, MD, MPH

Downloadable Slideset

Download this slideset from Jeremy Force, DO, MA; Nicholas McAndrew, MD, MSCE, and Sara M. Tolaney, MD, MPH with the most recent data for managing patients with HER2-positive advanced breast cancer.

person default Jeremy M. Force, DO, MA Nicholas P. McAndrew, MD, MSCE Sara Tolaney, MD, MPH Released: May 11, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

In partnership with
Supported by an educational grant from
Seattle Genetics

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?